QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 evercore-isi-group-maintains-outperform-on-boston-scientific-raises-price-target-to-81

Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform and raises the price target ...

Core News & Articles

- SEC Filing

 needham-reiterates-buy-on-boston-scientific-maintains-82-price-target

Needham analyst Mike Matson reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $82 price target.

 boston-scientific-adds-stroke-prevention-to-vascular-portfolio-via-silk-road-medicals-13b-deal

Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR sy...

Core News & Articles

Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Sil...

Core News & Articles

The per share price represents an approximate 38% premium to the volume-weighted average share price of Silk Road Medical's...

 goldman-sachs-initiates-coverage-on-boston-scientific-with-buy-rating-announces-price-target-of-90

Goldman Sachs analyst David Roman initiates coverage on Boston Scientific (NYSE:BSX) with a Buy rating and announces Price T...

 argus-research-maintains-buy-on-boston-scientific-raises-price-target-to-95

Argus Research analyst John Eade maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $80 to $95.

 citigroup-maintains-buy-on-boston-scientific-raises-price-target-to-87

Citigroup analyst Joanne Wuensch maintains Boston Scientific (NYSE:BSX) with a Buy and raises the price target from $85 to $87.

 reported-saturday-modular-atp-study-of-boston-scientifics-mcrm-system-meets-safety-and-efficacy-endpoints

In addition to evaluating the safety and performance of the EMPOWER LP as a standalone pacemaker, the trial evaluated the abili...

 jim-cramer-recommends-buying-this-sports-betting-companys-stock-i-think-its-terrific

Sports betting app DraftKings is "terrific," Cramer says. The company recently reported Q1 revenue of $1.18 billion, up...